Evidence map›Paper›PMID 36910668›Full record

ArticleFrontiers in oncology2023

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).

Xiao-Dong Jiao, Bao-Dong Qin, Zhan Wang, Ke Liu, Ying Wu, Yan Ling, Wen-Xing Qin, Miao-Miao Wang, Ling-Yan Yuan, Savio George Barreto and 30 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03239015 (Efficacy and Safety of Precision Therapy in Refractory Tumor), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03239015 phase2unknown statusnot on this map

Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway)

TypeinterventionalSponsorBaodong QinRan2017 to 2023Enrolled300ConditionsRare Tumor, Refractory TumorArmsGefitinib, Erlotinib, Afatinib, Trastuzumab, Oxazolidine
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Xiao-Dong JiaoDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Bao-Dong QinDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhan WangDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ke LiuDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ying WuDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yan LingDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Wen-Xing QinDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Miao-Miao WangDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ling-Yan YuanDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Savio George BarretoDepartment of Surgery, Flinders Medical Centre, Bedford Park, SA, Australia.
Anthony W KimDivision of Thoracic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, United States.
Kimberley MakDepartment of Radiation Oncology, Boston Medical Center, Boston University School of Medicine, Boston, MA, United States.
Hao LiDepartment of Medical Oncology, Shanghai Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.
Yuan-Yuan XuDepartment of Surgical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiao-Ming QiuLung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Min WuDepartment Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Min JinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li-Chao XuDepartment of Interventional Radiology, Shanghai Cancer Center, Fudan University, Shanghai, China.
Yi ZhongDepartment of Medical Oncology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hui YangDepartment of Medical Oncology, Suzhou Municipal Hospital, Nanjing Medical University, Suzhou, China.
Xue-Qin ChenDepartment of Medical Oncology, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yu ZengDepartment of Pathology, Shanghai Tongji Hospital, Shanghai Tongji University, Shanghai, China.
Jun ShiDepartment of Gastrointestinal Surgery, Changzhou No.2 People's Hospital, Nanjing Medical University, Changzhou, China.
Wen-Yu ZhuDepartment of Medical Oncology, Changzhou No.2 People's Hospital, Nanjing Medical University, Changzhou, China.
Qing-Qing DingDepartment of Geriatric Oncology, Jiangsu Provincial People's Hospital, Nanjing Medical University, Nanjing, China.
Wei JiaDepartment of Respiratory, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Su-Fen LiuDepartment of Gynecology, Changzhou No.2 People's Hospital, Nanjing Medical University, Changzhou, China.
Jun-Jing ZhouDepartment of Hepatobiliary and Pancreatic Surgery, Wuxi No.4 People's Hospital, Jiangnan University, Wuxi, China.
Hong ShenDepartment of Medical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Shi-Hua YaoDepartment of Thoracic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Zhao-Ji GuoDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ting LiDepartment of Medical Oncology, Shanghai Cancer Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Pei-Juan ZhouDepartment of Traditional Chinese Medicine, Shanghai Renji Hospital, Shanghai Jiaotong University, Shanghai, China.
Xue-Wei DongDepartment of Gastrointestinal Surgery, The First People's Hospital of Changzhou, Soochow University, Changzhou, China.
Wen-Feng LuDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Robert L ColemanDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Mehmet AkceDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States.
Chérif AkladiosDepartment of Obstetrics and Gynecology, University of Strasbourg, Strasbourg, France.
Francesco PuccettiDepartment of Gastrointestinal Surgery, San Raffaele Hospital IRCCS, Milan, Italy.
Yuan-Sheng ZangDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
NCI NIH HHS P30 CA013148
6 · The paper itself

Abstract

Purpose: We evaluated he effects of molecular guided-targeted therapy for intractable cancer. Also, the epidemiology of druggable gene alterations in Chinese population was investigated. Materials and methods: The Long March Pathway (ClinicalTrials.gov identifier: NCT03239015) is a non-randomized, open-label, phase II trial consisting of several basket studies examining the molecular profiles of intractable cancers in the Chinese population. The trial aimed to 1) evaluate the efficacy of targeted therapy for intractable cancer and 2) identify the molecular epidemiology of the tier II gene alterations among Chinese pan-cancer patients. Results: In the first stage, molecular profiles of 520 intractable pan-cancer patients were identified, and 115 patients were identified to have tier II gene alterations. Then, 27 of these 115 patients received targeted therapy based on molecular profiles. The overall response rate (ORR) was 29.6% (8/27), and the disease control rate (DCR) was 44.4% (12/27). The median duration of response (DOR) was 4.80 months (95% CI, 3.33-27.2), and median progression-free survival (PFS) was 4.67 months (95% CI, 2.33-9.50). In the second stage, molecular epidemiology of 17,841 Chinese pan-cancer patients demonstrated that the frequency of tier II gene alterations across cancer types is 17.7%. Bladder cancer had the most tier-II alterations (26.1%), followed by breast cancer (22.4%), and non-small cell lung cancer (NSCLC; 20.2%). Conclusion: The Long March Pathway trial demonstrated a significant clinical benefit for intractable cancer from molecular-guided targeted therapy in the Chinese population. The frequency of tier II gene alterations across cancer types supports the feasibility of molecular-guided targeted therapy under basket trials.

Indexed as

basket trialgene alterationintractable cancerprecision medicinetargeted therapy

Identifiers

PMID36910668
PMCPMC9995917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.